AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11306154 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine (ddI) plus stavudine (d4T) plus efavirenz (EFV) followed by zidovudine (ZDV) plus lamivudine (3TC) plus abacavir (ABC) plus nelfinavir (NFV)
Number of subjects: 1000
Study 11306154 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine (ddI) plus stavudine (d4T) plus nelfinavir (NFV) followed by zidovudine (ZDV) plus lamivudine (3TC) plus abacavir (ABC) plus efavirenz (EFV)
Number of subjects: 1000
Study 11306154 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine (ddI) plus stavudine (d4T) plus efavirenz (EFV) plus nelfinavir (NFV) followed by zidovudine (ZDV) plus lamivudine (3TC) plus abacavir (ABC) plus saquinavir plus ritonavir
Number of subjects: 1000
Study 11205489 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG 200 mg
Number of subjects: 20
Study 11205489 — intervention group
Group type: COMPARATOR
Intervention: Polyphenon E 200 mg
Number of subjects: 20
Study 11205489 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG 400 mg
Number of subjects: 20
Study 11205489 — intervention group
Group type: COMPARATOR
Intervention: Polyphenon E 400 mg
Number of subjects: 20
Study 11205489 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG 600 mg
Number of subjects: 20
Study 11205489 — intervention group
Group type: COMPARATOR
Intervention: Polyphenon E 600 mg
Number of subjects: 20
Study 11205489 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG 800 mg
Number of subjects: 20
Study 11205489 — intervention group
Group type: COMPARATOR
Intervention: Polyphenon E 800 mg
Number of subjects: 20
Study 9170990 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home coaching intervention
Number of subjects: 200
Study 8318879 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-delivered smoking cessation intervention
Number of subjects: 186
Study 8318879 — intervention group
Group type: COMPARATOR
Intervention: Usual care advice control condition
Number of subjects: 186
Study 3552639 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar electrocoagulation (EC group)
Number of subjects: 37
Study 3552639 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (control group)
Number of subjects: 37
Study 30402864 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-stent kissing technique + Rotational Wire (BSKT+RW)
Number of subjects: 80
Study 30402864 — intervention group
Group type: COMPARATOR
Intervention: Jailed wire technique (JWT)
Number of subjects: 80
Study 30402864 — intervention group
Group type: COMPARATOR
Intervention: Jailed balloon technique (JBT)
Number of subjects: 80
Study 30402864 — intervention group
Group type: COMPARATOR
Intervention: Balloon-stent kissing technique (BSKT)
Number of subjects: 80
Study 27983689 — intervention group
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A (100 units into each of the five lumbar extensor spinae muscles, total dose 500 to 1000 units)
Number of subjects: 37
Study 27983689 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 37
Study 27983689 — intervention group
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A
Number of subjects: 37
Study 25011722 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip device (Abbott Vascular) for mitral regurgitation
Number of subjects: 351
Study 22190441 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 91
Study 22190441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 91
Study 20921430 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan
Number of subjects: 849
Study 20921430 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 849
Study 20921430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study 18447940 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 159
Study 18447940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 15854167 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment (5 mg/kg for induction, plus two maintenance infusions 8 weeks apart)
Number of subjects: 14
Study 12878616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide with 1.5 MAC sevoflurane
Number of subjects: 10
Study 12878616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide with 1.0 MAC sevoflurane
Number of subjects: 10
Study 12878616 — intervention group
Group type: COMPARATOR
Intervention: Air-nitrous oxide
Number of subjects: 10
Study 12878616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HR and MAP
Number of subjects: 10
Study 10235439 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4g daily for 12 weeks)
Number of subjects: 57
Study 10235439 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (4g daily for 12 weeks)
Number of subjects: 57
Study 8909067 — intervention group
Group type: EXPERIMENTAL
Intervention: Betel nut chewing
Number of subjects: 28
Study 8909067 — intervention group
Group type: COMPARATOR
Intervention: Control (no betel nut chewing)
Number of subjects: 28
Study 1858085 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled 15-(s)-hydroxyeicosatetraenoic acid (15-HETE) 80 nmol
Number of subjects: 10
Study 1858085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium phosphate buffer)
Number of subjects: 10
Study 30160043 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/d melatonin supplements
Number of subjects: 70
Study 30160043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27100127 — intervention group
Group type: COMPARATOR
Intervention: None community use
Number of subjects: 399
Study 27100127 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive community use
Number of subjects: 399
Study 27100127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both passive and active community use
Number of subjects: 399
Study 24214797 — intervention group
Group type: EXPERIMENTAL
Intervention: Facecards
Number of subjects: 138
Study 24214797 — intervention group
Group type: COMPARATOR
Intervention: No Facecards (Control)
Number of subjects: 138
Study 22318996 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza hydrophilic extract (SMHE) for 60 days
Number of subjects: 62
Study 22318996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 20659225 — intervention group
Group type: EXPERIMENTAL
Intervention: High FODMAP diet (50 g/day)
Number of subjects: 30
Study 17965289 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase inhibitor nitro‐L‐arginine methyl ester (L‐NAME) at doses of 0.5, 1, 2, and 4 mg/kg intravenously over 60 min
Number of subjects: 14
Study 17965289 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase inhibitor nitro‐L‐arginine methyl ester (L‐NAME)
Number of subjects: 14
Study 17965289 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 ml normal saline)
Number of subjects: 14
Study 16310305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 80
Study 16310305 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 80
Study 14572573 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab maintenance therapy
Number of subjects: 573
Study 14572573 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab maintenance therapy
Number of subjects: 573
Study 14572573 — intervention group
Group type: COMPARATOR
Intervention: Single 5 mg/kg infliximab infusion (control group)
Number of subjects: 573
Study 11021165 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotting process evaluation
Number of subjects: 10
Study 8958890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (starting at 40 mg/day, reducing by 5 mg every other day)
Number of subjects: 413
Study 8958890 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fluticasone propionate (2 mg daily)
Number of subjects: 413
Study 1586049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal oxygen at 3 L/min delivered by concentrator
Number of subjects: 51
Study 1586049 — intervention group
Group type: COMPARATOR
Intervention: Room air at 3 L/min delivered by defective concentrator
Number of subjects: 51
Study 1586049 — intervention group
Group type: COMPARATOR
Intervention: N/A (no gas therapy)
Number of subjects: 51
Study 3857938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal pessary of 3 mg prostaglandin E2 (PGE2)
Number of subjects: 40
Study 3857938 — intervention group
Group type: COMPARATOR
Intervention: Intracervical 5‐mm laminaria tent (LT)
Number of subjects: 40
Study 30712148 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes with nicotine salt formulations
Number of subjects: 15
Study 30712148 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 15
Study 30712148 — intervention group
Group type: EXPERIMENTAL
Intervention: myblu 40-mg nicotine salt formulation
Number of subjects: 15
Study 30712148 — intervention group
Group type: EXPERIMENTAL
Intervention: All tested e-cigarettes
Number of subjects: 15
Study 30712148 — intervention group
Group type: EXPERIMENTAL
Intervention: All products tested
Number of subjects: 15
Study 28844522 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Care
Number of subjects: 60
Study 28844522 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 60
Study 27430941 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to 432 Hz music during endodontic treatment
Number of subjects: 100
Study 27430941 — intervention group
Group type: COMPARATOR
Intervention: No music during endodontic treatment
Number of subjects: 100
Study 24704126 — intervention group
Group type: COMPARATOR
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 230
Study 24704126 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 230
Study 22919757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Ganciclovir (7.5 mg/kg in inducement phase, 10 mg/kg in maintaining phase)
Number of subjects: 37
Study 22919757 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Ganciclovir (5 mg/kg in inducement and maintaining phases)
Number of subjects: 37
Study 22919757 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Ganciclovir
Number of subjects: 37
Study 20436079 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal propeptide of collagen IIA (PIIANP) measured at baseline and 4 years
Number of subjects: 160
Study 20436079 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal propeptide of collagen IIA (PIIANP) in anti-CCP positive patients
Number of subjects: 160
Study 20436079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-linked C-telopeptide of collagen II (CTX-II) measured at baseline and 4 years
Number of subjects: 160
Study 20436079 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoupling index for cartilage collagen metabolism calculated from PIIANP and CTX-II measurements
Number of subjects: 160
Study 18778469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg od
Number of subjects: 309
Study 18778469 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 25 mg od
Number of subjects: 309
Study 16171525 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-alpha alone (n = 19)
Number of subjects: 54
Study 16171525 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-alpha in combination with lamivudine (n = 35)
Number of subjects: 54
Study 16171525 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-alpha alone or in combination with lamivudine
Number of subjects: 54
Study 16171525 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 50)
Number of subjects: 54
Study 11841050 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin MZ-80 (150 mg t.i.d. per day)
Number of subjects: 60
Study 11841050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10099926 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite female orienteers
Number of subjects: 74
Study 10099926 — intervention group
Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 74
Study 8525871 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding size dimension
Number of subjects: 10
Study 8525871 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding both dimensions
Number of subjects: 10
Study 8525871 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding slow dimension
Number of subjects: 10
Study 8525871 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding fast dimension
Number of subjects: 10
Study 8525871 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 10
Study 2265044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC isoflurane
Number of subjects: 32
Study 2265044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC enflurane
Number of subjects: 32
Study 2265044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 MAC isoflurane
Number of subjects: 32
Study 2265044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 MAC enflurane
Number of subjects: 32
Study 2265044 — intervention group
Group type: COMPARATOR
Intervention: isoflurane
Number of subjects: 32
Study 2265044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 MAC groups
Number of subjects: 32
Study 229091 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective brain irradiation (EBI) with 2400 rad whole brain in 8 fractions over 10 days (NSD = 1130 ret)
Number of subjects: 55
Study 229091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EBI)
Number of subjects: 55
Study 229091 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 4 drug chemotherapy (lomustine, methotrexate, cyclophosphamide, vincristine) and radiotherapy (3000 rad to primary chest lesion).
Number of subjects: 55
Study 229091 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective brain irradiation (EBI)
Number of subjects: 55
Study 31317368 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing Internet results suggesting autism
Number of subjects: 0
Study 31317368 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing Internet results suggesting language delay
Number of subjects: 0
Study 31317368 — intervention group
Group type: COMPARATOR
Intervention: Not viewing Internet results
Number of subjects: 0
Study 29086498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4901
Study 29086498 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4901
Study 25500100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection (SR) with brachytherapy
Number of subjects: 212
Study 25500100 — intervention group
Group type: COMPARATOR
Intervention: Sublobar resection (SR)
Number of subjects: 212
Study 25500100 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 212
Study 25500100 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Number of subjects: 212
Study 25500100 — intervention group
Group type: EXPERIMENTAL
Intervention: T1b tumors
Number of subjects: 212
Study 25500100 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS
Number of subjects: 212
Study 23279003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 753
Study 23279003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 753
Study 23279003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (Initial Responders)
Number of subjects: 753
Study 23279003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (Initial Responders)
Number of subjects: 753
Study 23279003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (Partial Responders)
Number of subjects: 753
Study 23279003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (Partial Responders)
Number of subjects: 753
Study 23279003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 753
Study 22298147 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-nutrition education and IFA pediatric tablet intervention with parental involvement
Number of subjects: 0
Study 19623188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (21 schools)
Number of subjects: 42
Study 19623188 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 schools)
Number of subjects: 42
Study 16700770 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 79
Study 16700770 — intervention group
Group type: COMPARATOR
Intervention: Lecturing
Number of subjects: 79
Study 12650785 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. for 2 weeks
Number of subjects: 22
Study 12650785 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus ranitidine 300 mg HS for 4 weeks
Number of subjects: 22
Study 12650785 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg QAM and QHS for 2 weeks
Number of subjects: 22
Study 12650785 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every 8 hours for 2 weeks
Number of subjects: 22
Study 12650785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study 11242715 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with Lansoprazole (30 mg once a day), Amoxycillin (500 mg three times a day), and Roxythromycin (150 mg twice a day)
Number of subjects: 25
Study 11242715 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with Lansoprazole (30 mg once a day) and Amoxycillin (500 mg three times a day)
Number of subjects: 25
Study 8668506 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback on a correctly adjusted medium-sized figure
Number of subjects: 0
Study 8668506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 0
Study 8668506 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 0
Study 1387500 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 1 x 25 mg
Number of subjects: 34
Study 1387500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 1 x 2.5 mg
Number of subjects: 34
Study 6144456 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 312
Study 6144456 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg triazolam
Number of subjects: 312
Study 30916028 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 100%
Number of subjects: 58
Study 30916028 — intervention group
Group type: COMPARATOR
Intervention: FiO2 80%
Number of subjects: 58
Study 29613826 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis (DTS)
Number of subjects: 125
Study 27266443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0
Study 27266443 — intervention group
Group type: COMPARATOR
Intervention: Active Control Training (CT)
Number of subjects: 0
Study 24485487 — intervention group
Group type: EXPERIMENTAL
Intervention: 1μg of cosyntropin administered intravenously
Number of subjects: 45
Study 22894958 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV (tetravalent dengue vaccine)
Number of subjects: 1200
Study 22894958 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (placebo for first dose, licensed hepatitis-A for children, influenza vaccine for adolescents and adults)
Number of subjects: 1200
Study 19876613 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist circumference
Number of subjects: 4449
Study 19876613 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of the metabolic syndrome
Number of subjects: 4449
Study 19876613 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4449
Study 19876613 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 4449
Study 19876613 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4449
Study 19876613 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of amlodipine
Number of subjects: 4449
Study 19876613 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 4449
Study 19876613 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of diabetes
Number of subjects: 4449
Study 19876613 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of cardiovascular disease
Number of subjects: 4449
Study 17662087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice daily for 7 days
Number of subjects: 12
Study 17662087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15761089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Body Negative Pressure (LBNP) -20 mmHg
Number of subjects: 10
Study 15761089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Body Negative Pressure (LBNP) -40 mmHg
Number of subjects: 10
Study 15761089 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-Up Tilt (HUT)
Number of subjects: 10
Study 12038948 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of cevimeline 3 times daily
Number of subjects: 75
Study 12038948 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of cevimeline 3 times daily
Number of subjects: 75
Study 12038948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 10385778 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 143
Study 10385778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 10385778 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone with beta-blockade
Number of subjects: 143
Study 10385778 — intervention group
Group type: COMPARATOR
Intervention: Other patients (without beta-blockade)
Number of subjects: 143
Study 8529717 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert monitoring of inhalation
Number of subjects: 89
Study 8529717 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment (open randomized trial)
Number of subjects: 89
Study 8529717 — intervention group
Group type: COMPARATOR
Intervention: Physician prescribed doses of theophylline
Number of subjects: 89
Study 2224293 — intervention group
Group type: EXPERIMENTAL
Intervention: Active fitting (AF) programme of hearing aids
Number of subjects: 128
Study 392005 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsin (N-2-hydroxyethyl palmitamide)
Number of subjects: 1864